Treatment of lupus nephritis

Sebastian Dolff; Jo H. M. Berden; Marc Bijl

doi:10.1586/ECI.10.79

Treatment of lupus nephritis

Sebastian Dolff^*, Jo H. M. Berden, Marc Bijl

^*Corresponding author voor dit werk

Onderzoeksoutput › peer review

11 Citaten (Scopus)

Samenvatting

Renal involvement in systemic lupus erythematosus patients is a severe disease manifestation characterized by various clinical and histopathological alterations The revised International Society of Nephrology/Renal Pathology Society 2003 classification defines the subclasses of lupus nephritis (LN) according to their pathological glomerular patterns which has a crucial impact on the prognosis and treatment options for LN patients There are widely accepted therapeutic agents available such as cyclophosphamide mycophenolate mofetil azathioprine and corticosteroids Several trials have tried to determine a gold standard for induction and maintenance therapy in LN and the place of newer drugs biologicals has been investigated We review recently reported data on current treatment regimens in LN in particular in the context of the International Society of Nephrology/Renal Pathology Society 2003 classification

Originele taal-2	English
Pagina's (van-tot)	901-911
Aantal pagina's	11
Tijdschrift	Expert review of clinical immunology
Volume	6
Nummer van het tijdschrift	6
DOI's	https://doi.org/10.1586/ECI.10.79
Status	Published - nov.-2010

Toegang tot document

10.1586/ECI.10.79

Handle.net

Permanente koppeling

Citeer dit

@article{994105b942c1464abca7ab223a3e46bd,

title = "Treatment of lupus nephritis",

abstract = "Renal involvement in systemic lupus erythematosus patients is a severe disease manifestation characterized by various clinical and histopathological alterations The revised International Society of Nephrology/Renal Pathology Society 2003 classification defines the subclasses of lupus nephritis (LN) according to their pathological glomerular patterns which has a crucial impact on the prognosis and treatment options for LN patients There are widely accepted therapeutic agents available such as cyclophosphamide mycophenolate mofetil azathioprine and corticosteroids Several trials have tried to determine a gold standard for induction and maintenance therapy in LN and the place of newer drugs biologicals has been investigated We review recently reported data on current treatment regimens in LN in particular in the context of the International Society of Nephrology/Renal Pathology Society 2003 classification",

keywords = "glomerulonephritis, lupus nephritis, SLE, treatment, STEM-CELL TRANSPLANTATION, LONG-TERM PROGNOSIS, ANTI-DNA ANTIBODIES, MYCOPHENOLATE-MOFETIL, CONTROLLED-TRIAL, MEMBRANOUS NEPHROPATHY, INTRAVENOUS CYCLOPHOSPHAMIDE, RHEUMATOID-ARTHRITIS, MAINTENANCE THERAPY, DISEASE-ACTIVITY",

author = "Sebastian Dolff and Berden, {Jo H. M.} and Marc Bijl",

year = "2010",

month = nov,

doi = "10.1586/ECI.10.79",

language = "English",

volume = "6",

pages = "901--911",

journal = "Expert review of clinical immunology",

issn = "1744-666X",

publisher = "Taylor & Francis Group",

number = "6",

}

TY - JOUR

T1 - Treatment of lupus nephritis

AU - Dolff, Sebastian

AU - Berden, Jo H. M.

AU - Bijl, Marc

PY - 2010/11

Y1 - 2010/11

N2 - Renal involvement in systemic lupus erythematosus patients is a severe disease manifestation characterized by various clinical and histopathological alterations The revised International Society of Nephrology/Renal Pathology Society 2003 classification defines the subclasses of lupus nephritis (LN) according to their pathological glomerular patterns which has a crucial impact on the prognosis and treatment options for LN patients There are widely accepted therapeutic agents available such as cyclophosphamide mycophenolate mofetil azathioprine and corticosteroids Several trials have tried to determine a gold standard for induction and maintenance therapy in LN and the place of newer drugs biologicals has been investigated We review recently reported data on current treatment regimens in LN in particular in the context of the International Society of Nephrology/Renal Pathology Society 2003 classification

AB - Renal involvement in systemic lupus erythematosus patients is a severe disease manifestation characterized by various clinical and histopathological alterations The revised International Society of Nephrology/Renal Pathology Society 2003 classification defines the subclasses of lupus nephritis (LN) according to their pathological glomerular patterns which has a crucial impact on the prognosis and treatment options for LN patients There are widely accepted therapeutic agents available such as cyclophosphamide mycophenolate mofetil azathioprine and corticosteroids Several trials have tried to determine a gold standard for induction and maintenance therapy in LN and the place of newer drugs biologicals has been investigated We review recently reported data on current treatment regimens in LN in particular in the context of the International Society of Nephrology/Renal Pathology Society 2003 classification

KW - glomerulonephritis

KW - lupus nephritis

KW - SLE

KW - treatment

KW - STEM-CELL TRANSPLANTATION

KW - LONG-TERM PROGNOSIS

KW - ANTI-DNA ANTIBODIES

KW - MYCOPHENOLATE-MOFETIL

KW - CONTROLLED-TRIAL

KW - MEMBRANOUS NEPHROPATHY

KW - INTRAVENOUS CYCLOPHOSPHAMIDE

KW - RHEUMATOID-ARTHRITIS

KW - MAINTENANCE THERAPY

KW - DISEASE-ACTIVITY

U2 - 10.1586/ECI.10.79

DO - 10.1586/ECI.10.79

M3 - Review article

SN - 1744-666X

VL - 6

SP - 901

EP - 911

JO - Expert review of clinical immunology

JF - Expert review of clinical immunology

IS - 6

ER -

Treatment of lupus nephritis

Samenvatting

Toegang tot document

Handle.net

Vingerafdruk

Citeer dit